vimarsana.com

Page 4 - உணர்ச்சி ரோலின்ஸ் பள்ளி ஆஃப் பொது ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Georgia COVID-19 data adds important local dimension to national tracking tool

Tags » Emory University researchers have enhanced their dynamic national COVID-19 Health Equity Dashboard to provide more localized information on the impact of the pandemic in communities across Georgia. Georgia currently ranks 19th nationally with respect to COVID-19 deaths per capita, and there is a 10-fold difference in COVID-19 deaths by county across the state. “Some communities of Georgia have fared much worse than others in this pandemic. County data can help us understand where we might be falling short and where we are succeeding in pandemic response,” says Shivani Patel, PhD, MPH, who led a team of students and researchers that developed the dashboard.

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

Share this article Share this article INDIANAPOLIS, April 8, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28. Baricitinib-treated patients were 2.7 percent less likely than those receiving standard of care to progress to ventilation (non-invasive or mechanical) or death, a difference that was not statistically significant (odds ratio [OR]: 0.85; 95% CI 0.67, 1.08; p=0.1800). 

Research roundup: Recent grants and publications for Emory faculty and staff

Rollins receives $6 million grant from Gilead’s HIV initiative Emory’s Rollins School of Public Health has announced a $6 million grant from Gilead Sciences, Inc. over three years to continue to build the capacity of organizations working on the frontlines of the HIV crisis in communities across the Southern United States. Emory will serve as one of four Gilead COMPASS coordinating centers alongside the Southern AIDS Coalition, the University of Houston Graduate College of Social Work, and Wake Forest School of Divinity to provide direct support to local community organizations to help mitigate the HIV epidemic in the South.  This is part of a second wave of funding from Gilead, manufacturer of antiretroviral therapies for HIV/AIDS. Emory’s COMPASS coordinating center has directly distributed more than $4.3 million to 104 community organizations, and is directed by Neena Smith-Bankhead, director of capacity building and community engagement. More information here.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.